EATG » DELSTRIGO and PIFELTRO approved in Europe

DELSTRIGO and PIFELTRO approved in Europe

European Commission approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO™ (doravirine), an NNRTI, both for the treatment of HIV-1 in appropriate patients

Approvals based on findings from the pivotal Phase 3 DRIVE-AHEAD and DRIVE-FORWARD trials evaluating the efficacy and safety of DELSTRIGO and PIFELTRO through 96 weeks

Read the press release here.


 

Source:
Merck
News categories: HIV treatment, EMA/FDA